Less Atherosclerosis and Lower Blood Pressure for a Meaningful Life Perspective With More Brain
Jan A. Staessen, Tom Richart, Willem H. Birkenhäger T raditional teaching subdivides the dementia syndrome into neurodegenerative Alzheimer's disease (AD), vascular dementia (VaD), and mixed variants. In spite of the vast and continuing literature on the dichotomy between AD and VaD, new emerging concepts highlight the role of cardiovascular risk factors in the pathogenesis of AD, especially in older patients. 1, 2 Hypertension is the major player in the pathogenesis of stroke, poststroke dementia, and VaD. AD is the most common cause of dementia, contributing from 45% to Ͼ75% of the cases in Asians and whites, respectively. 3 This review will focus on the role of hypertension as a reversible risk factor in the development of dementia, in particular AD. To set the stage, we will first summarize current insights in the epidemiology of AD, the pathogenesis of VaD and AD, and the association between neurodegeneration and atherosclerosis.
Epidemiology of Dementia
Across 36 cross-sectional studies, the prevalence of dementia increased exponentially from 0.3% to 1.0% in subjects aged 60 to 64 years to 10% to 20% in octogenarians and to Ͼ40% in the ninth decade of life. 3 In 15 longitudinal studies, the incidence of dementia showed a similar age-related dependency with rates expressed in new cases per 1000 personyears ranging from 0.4 to 4 at 60 to 64 years to 20 to Ͼ40 at 80 to 85 years. 3 Currently, 24.3 million people have dementia with an annual worldwide incidence of 4.6 million new cases. 4 Because of the aging of populations, the number of demented patients will increase 2-fold every 20 years to 81.1 million by 2040, with Ͼ60% living in developing countries. 4 The 2003 World Health Report 5 estimated that adults aged Ն60 years lost Ϸ8.6 million disability-adjusted life years because of AD or other dementias. In this age group, only ischemic heart disease (31.5), cerebrovascular disease (29.6), and chronic obstructive pulmonary disease (14.4) caused more premature disability and mortality. 5 In the United States, the number of demented patients with roughly triple, from 4.6 million in 1998 to 16 million by 2050. 6 
Pathogenesis of Dementias VaD
Poststroke dementia is the most common form of VaD. In a case-control study nested within the Framingham cohort, the relative risk of dementia in stroke survivors compared with controls varied from 2.0 to 2.8, depending on the covariates considered for adjustment. 7 Of the incident dementia cases, 51% were diagnosed as having VaD or mixed dementia, whereas this proportion was only 4% among the control subjects without a history of stroke. 7 VaD may result from a single stroke interrupting brain circuits critical for memory and cognition (strategic infarct dementia) or from multiple strokes (multi-infarct dementia). 8, 9 Of particular importance in older patients is subcortical small vessel disease of the medullary arteries, which perpendicularly penetrate the brain cortex into the subjacent white substance without intertwining branches other than very fine capillaries, thus constituting many independent small vascular territories. Exposure of these small brain vessels to highly pulsatile pressure and flow explains microvascular damage, 10 resulting in white matter damage, lacunas, and loss of cortical connections. 8 Multiple infarction dementia exhibits a stepwise but unpredictable course, depending on the size, localization, and number of ischemic insults. 9 Subcortical VaD has a more insidious character without sensory-motor manifestations but with progressive changes in personality, mood, behavior, or cognition ( Figure 1 ).
AD
AD is a neurodegenerative disease with an inexorably progressive, disabling and fatal course (Figure 1) , of which the clinically overt phase usually spans from 3 to 10 years. 2 The disease primarily affects cholinergic neurotransmission in the medial temporal lobe, the entorhinal cortex, and the hippocampus. 1, 2 Interaction between these brain structures plays a crucial role in memory consolidation, memory optimization during sleep, and spatial orientation. The prevailing viewpoint on the pathogenesis of AD rests on the extraneuronal and intraneuronal accumulation of misfolded protein, amy-loid ␤-peptide (A␤), which starts a pathogenetic cascade resulting in neurotoxicity. 2 A␤ has selective toxicity for the hippocampus and entorhinal cortex, while sparing the cerebellum. Deposits of A␤ form senile plaques. Neurofibrillary tangles are the second histopathologic hallmark of AD. 2 They consist of hyperphosphorylated microtubule-associated protein . They aggregate as pairs of filaments that twist around one another: so-called paired helical filaments. These filamentous inclusions displace organelles, destabilize the cytoskeleton, and impair axoplasmatic flow, thereby affecting nutrition of axon terminals and dendrites.
Mild cognitive impairment indicates a syndrome defined as a cognitive decline greater than expected for an individual's age and education. In adults Ͼ65 years of age, it has a prevalence ranging from 3% to 19%. 11 Many patients with mild cognitive impairment have minor histopathologic AD changes, and more than half progress to full blown AD. 11, 12 
Neurodegeneration and Atherosclerosis
Accumulating evidence suggests a strong link among AD, cardiovascular risk factors, and atherosclerosis. In multivariate-adjusted longitudinal studies, the incidence of dementia independently increased with pre-existing cardiovascular disease, the metabolic syndrome, skinfold thickness, body mass index, hypercholesterolemia, diabetes mellitus, hyperhomocysteinemia, smoking, and/or high-sensitivity C-reactive protein, whereas higher education, more exercise at middle age, and moderate alcohol consumption were protective. 1, 13 Neuroimaging 14 and postmortem histopathologic 15 studies indicate that up to one third of AD patients have some degree of vascular pathology, whereas in a similar proportion of VaD patients AD lesions are also present. The summation of vascular brain lesions, white matter damage reflecting small vessel disease, and typical AD pathology interactively lead to dementia, even when each type of lesion, on its own, would not be severe enough to cause dementia. 9 Moreover, recent evidence suggests that cholinergic neuronal processes are not only involved in cognition, per se, but in the preservation of cerebral blood flow as well ( Figure 2 ). Indeed, cholinergic agents stimulate regional cerebral blood flow in patients with AD or VaD. 16 Experimental studies likewise support the convergence between A␤ and vascular factors in the pathogenesis of dementia. A␤ constricts human cerebral arteries. 17 A␤ attenuates endothelium-mediated dilatation in cerebral arteries by production of reactive oxygen radicals and impairs the increase in neocortical blood flow in response to somatosensory activation. 18 Furthermore, transgenic mice overexpressing mutated forms of amyloid precursor protein, from which misfolded A␤ originates, show a reduction in resting 17 and stimulated 18 cerebral blood flow and an impaired autoregulation of the cerebral circulation. 19 Human platelets contain membrane-associated amyloid precursor protein. 20 Macrophages in human carotid plaque, which phagocytize platelets after intraplaque microhemorrhages, can process amyloid precursor protein into A␤. 20 Other studies suggest the involvement of cholesterol metabolism in the pathogenesis of AD. In cell cultures, increased 21 and decreased 22 cholesterol concentrations stimulate or repress the generation of A␤ from amyloid precursor protein, respectively. The apolipoprotein E 4 allele represents a major risk factor for AD in all ethnic groups, across all ages between 40 and 90 years, and in both women and men. 23 The 4 allele enhances the risk 3-fold in heterozygotes and by a factor 15 in homozygotes. 23 Each allele copy lowers the age of onset by Ϸ10 years. 24 Apolipoprotein E acts as a cholesterol transporter in the brain, with the 4 variant being less efficient in the reuse of membrane lipids and neuronal repair. 25 The 3 and 4 variants play a critical and isoformspecific role in plaque formation. 26 The apolipoprotein E 4 allele accounts for most of the genetic risk in AD. 1, 2 
Blood Pressure as Risk Factor for Dementia
In middle-aged and older adults, hypertension is the predominant and most frequent cardiovascular risk factor. Any man normotensive at 50 years has a probability of Ͼ90% to become hypertensive during the remainder of his lifetime. 27 Studies on the association between cognition and blood pressure can be subdivided into those with a cross-sectional versus longitudinal design. The end point in these studies can be disease outcomes, such as dementia, AD, or VaD; morphological or functional alterations of the brain, as documented by histopathologic autopsy studies or modern neuroimaging techniques; or cognitive function, as assessed by batteries of tests, each covering varying cognitive domains, or more global tests of cognition, such as the Mini Mental State Examination, or composite scores of specific tests.
Cross-Sectional Studies
Cross-sectional studies, reviewed elsewhere, 28 observed positive and independent associations of blood pressure, analyzed as a continuous or dichotomized variable, with cognitive impairment as assessed by the Mini Mental State Examination or multiple cognitive tests. By contrast, other cross-sectional studies did not find any association or noticed a U-shaped relation.
Cross-sectional studies, in which outcome and exposure are simultaneously recorded, obviously have limited capability to assess the association between cognition and blood pressure. The extensive lag phase between the onset of hypertension and subsequent cognitive impairment together with the insidious clinical course of neurodegenerative dementia necessitate long-term prospective studies. Histological lesions, such as neurofibrillary tangles or an accelerated rate of neuronal atrophy in the medial temporal lobe of the brain, for decades, may precede overt dementia. Two Framingham reports 29, 30 dramatically illustrated the shortfall of the crosssectional approach. In stroke-free Framingham participants, there was no relation between the scores of 8 cognitive tests, administered in 1976 -1978, and the concurrently measured blood pressure, irrespective of whether the analysis included or excluded patients on antihypertensive drug treatment. 29 However, higher blood pressure levels over 5 earlier biennial examinations (1956 -1964) , when few hypertensive patients were taking antihypertensive medications, significantly predicted lower scores of attention, memory, and global cognition in 1976 -1978 . 30 This inverse temporal association was consistent for systolic and diastolic blood pressure and withstood adjustment for sex, age, cigarette smoking, alcohol consumption, education, and occupation. 30 
Longitudinal Cohort Studies
In 1996, Skoog et al 31 published one of the first longitudinal studies on the incidence of dementia in relation to blood pressure. They recruited 382 nondemented 70-year-old residents of Göteborg, Sweden (57.8% women), of whom 302, 205, and 94 were available for reassessment at 75, 79, and 85 years, respectively. Participants who developed dementia at age 79 to 85 had higher systolic blood pressure at 70 years (178 versus 164 mm Hg) and higher diastolic blood pressure at ages 70 (101 versus 92 mm Hg) and 75 (97 versus 90 mm Hg). 31 Patients specifically developing AD or VaD had higher diastolic blood pressure at ages 70 and 75, respectively. 31 Although based on relatively few subjects, the seminal report by Skoog et al 31 set the stage for subsequent studies published in the second half of the 1990s. [32] [33] [34] [35] These multivariate-adjusted analyses confirmed that at a relatively high diastolic blood pressure (Ն75 mm Hg versus Յ70 mm Hg) at age 50, 32 a persistently elevated systolic blood pressure (Ն140 mm Hg) at ages ranging from 43 34 to 75 33 years, or stage 2 hypertension (Ն160 mm Hg systolic and Ն95 mm Hg diastolic) within the 59 to 71 age bracket 35 consistently predicted worse cognitive performance [32] [33] [34] [35] or more severe white-matter lesions 34 at ages ranging from 63 35 to 79 34 years. To further clarify the role of blood pressure in the pathogenesis of cognitive impairment, we performed a systematic review of the prospective studies published since 2000 until early 2006, from which we extracted or computed summary statistics. The outcome variables were either levels of or changes in single or composite cognitive scores (Table 1) [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] ; the incidence of cognitive dysfunction, dementia, AD, or VaD (Table 2) 42,48 -61 ; or the appearance of brain lesions in histopathologic or neuroimaging studies (Table 3) . [62] [63] [64] [65] For each of these 3 end points, we ordered the reports according to the age at enrollment.
All of the studies of cognitive function, involving subjects on average Ͻ70 years old at enrollment (Table 1) , 36 -41 uniformly showed a significantly lower performance or a more rapid decline of cognitive function with higher blood pressure, although in 1 cohort only for stage 3 hypertension. 41 At more advanced age, [42] [43] [44] [45] [46] [47] point estimates went in the same direction but only reached significance in the normotensive Hispanic Established Populations for Epidemiologic Studies of the Elderly cohort 44 and in the Active Cognitive Training for Independent and Vital Elderly Trial. 46 Among the studies with cognitive impairment as a categorical end point (Table 2) , 42,48 -61 those using a dichotomized test score 53, 57 classified from 15% 53 to 50% 57 of the participants as cognitively impaired and reported positive associations with hypertension. Two studies 50, 56 found no association of mild cognitive impairment with hypertension earlier in life. Studies with dementia, 48, 52, 54 AD, 42,49,51,52,54,55,58 -61 or VaD 49, 54, 59 as the end point demonstrated a significantly positive association with Ն1 blood pressure index, if follow-up started from middle age rather than old age. 48, 51, 52, 54 Remarkably, 1 study found an inverse association of AD with blood pressure in subjects recruited at the upper end of the age spectrum (mean age 87 years). 55 In keeping with the estimates listed in Table 2 , the Baltimore Longitudinal Survey of Aging, based on 11 years of multivariate adjusted follow-up of 847 subjects (mean age: 70.6 years; 41% women) described age as an important modifier of the effects of blood pressure on cognition. 66 Among younger participants (60 years at baseline), those with higher systolic blood pressure performed worse on tests of nonverbal memory and confronting naming, although the test results improved over time because of a learning effect. 66 Among older participants (80 years), those with higher systolic blood pressure not only performed worse than subjects with normal blood pressure, but also experienced a decline in cognitive performance over time. 66 In summary, our overview shows that hypertension, especially when already present at middle age, adversely affects cognition later in life. In old and very old adults, the association between impaired cognition and hypertension becomes weaker and more difficult to demonstrate, perhaps because, in prospective population studies, diastolic blood pressure decreases after age 50 67 or because systolic blood pressure falls in the very old. 31 Finally, 1 autopsy report 62 and 3 brain imaging studies [63] [64] [65] with longitudinal perspective observed independent and positive associations between brain lesions and blood pressure indexes (Table 3) . [62] [63] [64] [65] 
Low Blood Pressure as Manifestation of Dementia
Already in 1996, Skoog et al 31 noticed that with advancing age all of the subjects in his study experienced a decrease in blood pressure but that the fall in systolic and diastolic blood pressure was larger in patients who developed dementia than in their nondemented counterparts. A retrospective review of the medical charts of 1133 women (Ն75 years) covering 10 years 68 revealed that systolic blood pressure increased with time in 568 unimpaired subjects but that it increased less in 274 and 291 women who either developed cognitive impairment or became demented. Diastolic blood pressure declined significantly with time in all 3 of the groups. 68 In a cohort of 242 French patients with moderate AD (mean age: 78 years; 74% women) 69 blood pressure significantly fell over 1 year of follow-up, independent of sex, age, body mass index, and antihypertensive drug treatment.
Progressive physical inactivity in those blemished by advancing mental deterioration may be a substantial factor leading to a fall in blood pressure in the years immediately preceding and after overt dementia. In addition, neuronal death and defective cholinergic neurotransmission affecting the autonomic centers in the brain probably results in a dysregulation of blood pressure (Figure 2 ). Orthostatic or postprandial dips in blood pressure, pari passu with episodes of impaired cerebrovascular blood flow, might actually contribute to further brain damage, sustaining a perpetuating vicious circle. 70 
Reversibility of Risk Associated With Hypertension Nonrandomized Observational Studies
Ten prospective studies (Table 4) 35,71-79 explored in multivariate-adjusted analyses the possible influence of antihypertensive treatment on the incidence of cognitive impairment or overt dementia. Differences in the definition of the cognitive end point, the wide range of age at baseline and duration of follow-up, varying sampling frames, and adjustment for different sets of covariates or effect modifiers, such as the apolipoprotein E 4 polymorphism, 35, 79 made the computation of a pooled association size impossible. Nevertheless, of the 10 studies (Table 4) , 35, [71] [72] [73] [74] [75] [76] [77] [78] [79] 8 reported that antihypertensive drug treatment lowered the risk of cognitive decline, the reduction being significant in 5 reports, 71, 72, 75, 77, 78 and proportional to duration of treatment. 80 No single study observed a multivariate-adjusted significantly elevated risk in treated hypertensive patients. Several researchers tried to dissect the correlation between cognitive impairment and antihypertensive treatment according to the main classes of antihypertensive drugs (Table Abbreviations: N indicates No. of subjects; FU, average follow-up; F, proportion of women; CVA, patients with stroke; BP, average blood pressure at baseline (percentage of hypertensive patients). "Ϸ" indicates estimates derived from the total study population and taken as representative for a subgroup, statistics computed from reported data, or P values computed by a normal approximation from the confidence interval. ". . ." represents unreported information that could not be estimated. Studies were ordered according to age at enrolment. End points: ⌬CSR indicates changes in the composite of 3 test scores reflecting reasoning; DS, digit span test score; ⌬DSS, difference in change over time in the digit symbol subtest of the Wechsler Adult Intelligence Test (Revised) vs normotensive subjects; ⌬MMSE, estimated change in the Mini Mental State Examination score over the whole follow-up period; ⌬SCCS, annual change in standardized composite cognitive score; ⌬SPMS, 3-year change in score obtained by Short Portable Mental Status questionnaire; ⌬V/FC, annual change in the visualization/fluid composite score as derived from the Wechsler Adult Intelligence Test; VF, verbal fluency test score.
Covariates: A indicates age; AHT, antihypertensive drug treatment; ⌬AHT, institution of antihypertensive treatment; ALC, alcohol intake; BMI, body mass index; ⌬BMI, change in body mass index; BPB, blood pressure at baseline; C, center; CHL, hypercholesterolemia or serum cholesterol; CTB, cognitive tests at baseline; CVA, stroke; DM, diabetes mellitus; DPR, depression; ED, education; FU, follow-up duration; HD, heart disease; INC, income; MS, marital status; OCC, occupation; PA, physical activity; PAD, history of peripheral artery disease; PSM, psychotropic medication; R, race; RIG, randomized intervention group; S, sex; SMK, smoking.
Blood pressure indexes at baseline: DP/SP indicates diastolic (ϩ5 mm Hg)/systolic (ϩ10 mm Hg) blood pressure; ⌬DP/⌬SP, change from baseline in diastolic/systolic blood pressure (ϩ1 mm Hg); HT, hypertension; HT2/HT3, stage 2/3 hypertension; UHT, uncontrolled hypertension.
Effect size: score of cognitive test or change in test score associated with blood pressure indexes on a continuous or categorical scale. Abbreviations: N indicates No. of subjects; FU, average follow-up; F, proportion of women; CVA, patients with stroke; BP, average blood pressure at baseline (percentage of hypertensive patients). "Ϸ" indicates estimates derived from the total study population and taken as representative for a subgroup, statistics computed from reported data, or P values computed by a normal approximation from the CI. ". . ." represents unavailable information that could not be estimated. Studies were ordered according to age at enrolment.
Acronyms Covariates: A indicates age; AHT, antihypertensive drug treatment; ALC, alcohol intake; BMI, body mass index; C, cohort; CHL, hypercholesterolemia or serum cholesterol; CTB, cognitive tests at baseline; CVA, history of stroke; DM, diabetes mellitus; E4, No. of APOE 4 alleles; ED, education; FU, follow-up duration; HD, history of heart disease; MRI, brain lesions identified by MRI at baseline; MLK, milk intake; PAD, history of peripheral artery disease; R, race; S, sex; SMK, smoking.
Blood pressure indexes at baseline: DP/SP indicates diastolic (ϩ5 mm Hg)/systolic (ϩ10 mm Hg) blood pressure; DH1/DH2, diastolic blood pressure 90 to 94 mm Hg/Ն95 mm Hg; DH1-T/DH2-T, diastolic blood pressure 90 to 94/Ն95 mm Hg in the absence of antihypertensive treatment; HT, hypertension; HTϪIS/HTϩIS, hypertension without/with intervening stroke; SH, systolic hypertension; SH1/HT2, stage 1/2 systolic hypertension; SH1-T/SH2-T, stage 1/2 systolic hypertension in the absence of treatment; SH2ϪE4/SH2ϩE4, stage 2 systolic hypertension in absence/presence of the APOE 4 allele. Abbreviations: N indicates No. of subjects; FU, average follow-up; F, proportion of women; CVA, patients with stroke; and BP, average blood pressure at baseline (percentage of hypertensive patients). "Ϸ" indicates P values computed by a normal approximation from the CI. ". . ." represents unavailable information that could not be estimated. Studies were ordered according to age at enrolment.
TABLE 3. Association Between Brain Lesion and Blood Pressure Indexes
Study acronym: HAAS indicates Honolulu Asia Aging Study. End point: CAS indicates cortical atrophy score on MRI of the brain; NFTH/NFTN, count ratio vs normal blood pressure for neurofibrillary tangles in hippocampus/neocortex; NPH/NPN , count ratio vs normal blood pressure for neuritic plaques in hippocampus/neocortex; WMH, white-matter hyperintensities; WMLS, subcortical white matter lesions defined as the upper fifth of the distribution according to severity.
Covariates: A indicates age; AHT, antihypertensive drug treatment; BMI, body mass index; DM, diabetes mellitus; E4, No. of APOE 4 alleles; S, sex; SMK, smoking. Blood pressure indexes at baseline: DH2 indicates diastolic blood pressure Ն95 mm Hg; DP, diastolic blood pressure (ϩ5 mm Hg); DPϪT/ DPϩT, diastolic blood pressure (ϩ5 mm Hg) in the absence/presence of antihypertensive treatment; HTϽ5/HTϽ20, hypertension present for Ͻ5/20 years; HTϾ5,HTϾ20, hypertension present for Ͼ5 or 20 years; SH2, stage 2 systolic hypertension; SP, systolic blood pressure (ϩ 10 mm Hg); SPA, systolic blood pressure on daytime ambulatory measurement (ϩ10 mm Hg).
Effect size: relative risk associated with exposure variable except for CAS, for which the difference associated with a 5 mm Hg higher diastolic blood pressure at baseline is given.
reverse causality, patients with more severe hypertension being more likely to be treated, self-selection of patients consenting to follow-up, and the arbitrary nonrandomized definition of the drug class used as reference.
Randomized Clinical Trials
The trial conducted by the Medical Research Council in older adults 81 was the first outcome study that investigated the effects of antihypertensive drug treatment on cognitive func- Antihypertensive drugs: A indicates angiotensin-converting enzyme inhibitors; C, calcium-channel blockers; Cd, dihydropyridine calcium channel blockers; Cnd, nondihydropyridine calcium channel blockers; D, diuretics; Dp, potassium-sparing diuretics.
End points: CI, cognitive impairment defined as dementia or poor performance on screening and/or repeat cognitive testing; DEM, dementia; MCI, mild cognitive impairment.
Covariates: A indicates age; ALC, alcohol intake; BMI, body mass index; BP, blood pressure; CHL, total, high-and low-density lipoprotein cholesterol or hypercholesterolemia; CSID, score of Community Screening Instrument for Dementia at baseline; CVA, stroke; CVD, cardiovascular disease; DM, diabetes mellitus; DPR, depression; E4, No. of APOE 4 alleles; ED, education; FHD, family history of dementia; HD, heart disease; HT, hypertension; IS, living independently as opposed to sheltered care; MMSE, score of Mini Mental State Examination at baseline; PAD, peripheral artery disease; R, race; S, sex; SMK, smoking; SF, sampling frame; SBP, systolic blood pressure; S/DBP, systolic and diastolic blood pressure.
Effect size: relative risk associated with antihypertensive drug treatment.
tion. The patients were randomly assigned to a diuretic (hydrochlorothiazide plus amiloride), a ␤-blocker (atenolol), or placebo. 81 Both active treatments reduced blood pressure below the placebo level. Over a period of 54 months, 2584 patients underwent elaborate psychometric tests. 81 No significant differences in the test scores occurred. However, follow-up of 387 surviving Medical Research Council patients for 9 to 12 years revealed that less decline in systolic blood pressure led to a poorer cognitive outcome, even with adjustments applied for a family history of dementia, cognitive function at baseline, aging, and alcohol intake. 82 The Medical Research Council study, 81 unfortunately, did not report on the incidence of overt dementia. In 4 outcome trials of blood pressure lowering treatment, [83] [84] [85] [86] dementia was a secondary outcome in its own right. The double-blind placebo-controlled Systolic Hypertension in the Elderly Program (SHEP) 83 included 4736 patients with a mean age of 72 years. Active treatment consisted of chlorthalidone with the possible addition of atenolol or reserpine. SHEP failed to demonstrate a significant effect of antihypertensive treatment on the incidence of dementia (Figure 3 ) despite betweengroup blood pressure differences Ͼ10 mm Hg systolic and 4 mm Hg diastolic. The rates on placebo and active treatment were 4.2 and 3.6 cases per 1000 patient-years (relative risk reduction; RRR: 14%; 95% CI: Ϫ26% to 54%; Pϭ0.44). 83 A subsequent report 87 noticed that, although retention to the clinical examinations was very high, SHEP patients who missed cognitive assessments were more likely to be older, less educated, nonwhite, randomly assigned to placebo, and to have a higher occurrence of nonfatal cardiovascular events before each follow-up visit. The interpretation was that selective attrition might have biased the SHEP dementia results toward the null hypothesis of no differences between the treatment groups. 87 In the double-blind placebo-controlled Systolic Hypertension in Europe Trial, active treatment consisted of the dihydropyridine calcium-channel blocker, nitrendipine, which could be combined with enalapril, hydrochlorothiazide, or both add-on drugs to achieve blood pressure control. 13 Median follow-up lasted only 2 years. The trial had to be stopped prematurely, because active treatment resulted in a 42% decrease in the primary end point of fatal and nonfatal stroke. Of 4695 randomly assigned patients, 2418 participated in the substudy on dementia (mean age: 70 years). 13 Compared with placebo, active treatment reduced blood pressure by 8.3 mm Hg systolic and 3.8 mm Hg diastolic and the incidence of dementia by 50% from 7.7 to 3.8 cases per 1000 patient-years. 13 After the double-blind trial had stopped in 1997, all of the patients were offered therapy with the same active medication. Median follow-up lengthened to 3.9 years. The number of dementia cases doubled from 32 to 64 (41 with Alzheimer's disease). 84 Immediate compared with delayed antihypertensive therapy reduced the risk of dementia by 55% (CI: 24% to 73%; PϽ0.001) from 7.4 to 3.3 cases per 1000 patient-years ( Figure 3) . 84 In the Perindopril Protection Against Recurrent Stroke Study, 85 combination therapy with perindopril plus indapamide (RRR: 23%; CI: 0% to 41%; Pϭ0.05) but not monotherapy with perindopril alone (RRR: Ϫ8%; CI: Ϫ48% to 21%; Pϭ0.60), compared with placebo, reduced the incidence of dementia in 6105 patients with pre-existing cerebrovascular disease (mean age: 64 years). The systolic/diastolic blood pressure differences averaged 12/5 mm Hg and 5/3 mm Hg in the combination therapy and monotherapy arms, respectively. There was no apparent effect of active treatment among participants (16.4%) with evidence of cognitive impairment at baseline (RRR: Ϫ5%; CI: Ϫ42% to 22%; Pϭ0.70), whereas among patients without such impairment (84.2%), active treatment protected against poststroke dementia (RRR: 31%; CI: 6% to 49%; Pϭ0.02). 85 The Study on Cognition and Prognosis in the Elderly was set up as a double-blind, placebo-controlled trial in 4964 patients (mean age: 76 years). 86 However, open-label antihypertensive drugs, which mainly consisted of diuretics, ␤-blockers, or both classes of old drugs, were added to the double-blind study medication in a considerably greater proportion of the patients randomly assigned to placebo than in those allocated candesartan. 86 The achieved blood pressure was 3.2/1.6 mm Hg lower in the candesartan group. In a posthoc analysis, 88 patients with cognitive impairment at baseline (Mini Mental State Examination score: 24 to 28) experienced less further decline in this test on candesartan than in the control group.
Overall, the 4 dementia trials [83] [84] [85] [86] included 18 196 patients and 642 dementia cases. The P value for heterogeneity across trials was not significant (Pϭ0.18). Based on a fixed-effects model, the pooled odds ratio for the prevention of dementia was 0.89 (CI: 0.75 to 1.04) and did not reach statistical 84 ) and the SHEP 83, 87 . In the Syst-Eur trial, the number of cases of new-onset AD was 29 of 43 and 12 of 21 in the patients randomly assigned to placebo and active treatment, respectively. 84 The corresponding incidence of vascular dementia was 12 of 43 and 7 of 21. 84 The SHEP reports 83, 87 did not differentiate between AD and VaD.
significance (Pϭ0.15). However, sensitivity analyses revealed a difference in the pooled odds ratios, depending on whether active treatment started with an inhibitor of the renin system or not (Figure 4 ) . The pooled odds ratios were 0.75 (CI: 0.60 to 0.94; Pϭ0.01) for SHEP, 83 Systolic Hypertension in Europe, 84 and the combination therapy arm of Perindopril Protection Against Recurrent Stroke Study 85 85 The difference between the latter summary statistics was significant (Pϭ0.04).
Perspectives and Conclusions
Although hypertension has long been recognized to play a central role in the pathogenesis of VaD, our review underscores that it is an equipotent risk factor for AD. Early treatment of hypertension is an effective way to prevent dementia, including AD. Our review also illustrates that research into dementia requires a comprehensive multidisciplinary approach, in which basic researchers, neurologists, geriatricians, and cardiovascular physicians should join forces. Reviewers and editors can facilitate this process. In scrutinizing submitted research articles, they might adhere to more stringent standards with regard to the diagnostic instruments that have been administered, and they might check whether essential confounders have been sufficiently accounted for. Lack of standardization in the conduct and analysis of studies prevented the computation of pooled statistic from Tables 1 to 4 . Finally, publication of cross-sectional and nonrandomized studies, which only provide the lowest level of scientific evidence and which, at best, are hypothesis generating, should be discouraged in favor of prospective surveys and randomized clinical trials, respectively. Effects of blood pressure-lowering treatment on the incidence of dementia in placebo-controlled trials. f, odds ratios in individual trials and have a size proportional to the inverse of the variance of the odds ratios. Horizontal lines and ࡗ, 95% CIs for individual trials and summary statistics, respectively. Pooled estimates were computed from a fixed-effect model. Three trials refers to SHEP, 83 Syst-Eur, 84 and PROGRESS combined treatment with perindopril and indapamide. 85 The vertical dotted line marks the position of the point estimate of the pooled effect sizes for all trials combined.
